title: [Metabolic therapy of postperitoneal intoxication].
abstract: This clinico-laboratory study showed that antihypoxant remaxol promoted normalization of lipid metabolism in acute peritonitis and significantly reduced membrane-destabilizing events. This resulted in rapid elimination of the inflammatory process in the abdominal cavity and lowering of the intensity of endogenous intoxication. This beneficial effect decreased the severity of myocardial lesions and resulted in the normalization of erythrocyte function. It is concluded that the regulatory action of remaxol on lipid metabolism is due to its ability to control free radicals in lipid peroxidation and reduce phospholipase A2 activity.
authors.forename: A P
authors.initials: AP
authors.lastname: Vlasov
authors.forename: S G
authors.initials: SG
authors.lastname: Anaskin
authors.forename: T I
authors.initials: TI
authors.lastname: Vlasova
authors.forename: S M
authors.initials: SM
authors.lastname: Chivisov
authors.forename: V A
authors.initials: VA
authors.lastname: Shibitov
authors.forename: I V
authors.initials: IV
authors.lastname: Potyanova
authors.forename: P V
authors.initials: PV
authors.lastname: Selentsov
mesh_terms: D000208:Acute Disease; D004912:Erythrocytes / Q000378:metabolism; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D015227:Lipid Peroxidation / Q000187:drug effects; D009206:Myocardium / Q000473:pathology*; D010538:Peritonitis / Q000188:drug therapy* / Q000503:physiopathology; D054467:Phospholipases A2 / Q000378:metabolism; D012720:Severity of Illness Index; D013386:Succinates / Q000627:therapeutic use*
chemical_list: D005609:Free Radicals; C555877:Remaxol; D013386:Succinates; D054467:Phospholipases A2